BioNeutral Group CEO, Stephen J. Browand, stated "The validation of this rigorous testing protocol, which utilizes real world soiled conditions in a 1 to 10 diluted form, is very exciting. What this will mean is that all countries worldwide will be able to afford an effective combatant to the H1N1 virus, even those with major economic challenges.

Chief Scientist at BioNeutral Group, Dr. Andrew Kielbania stated Independent laboratory testing of our Ygiene?„? Antimicrobials is an integral aspect of our new product development process and the EPA registration process. These new independent lab results continue to verify the exceptional efficacy and speed to kill of our Ygiene?® antimicrobials. Consistent with our strategy on antimicrobial performance we not only actually test against the microorganisms on which we intend to base our EPA application, we also test in the presence of organic soil to better simulate real world conditions. In the end, it is performance in those real world conditions that will distinguish Ygiene?® from its competitors.

www.bioneutralgroup